New England Research & Management Inc. Has $2.40 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

New England Research & Management Inc. grew its position in United Therapeutics Co. (NASDAQ:UTHR) by 29.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,430 shares of the biotechnology company’s stock after buying an additional 2,395 shares during the period. United Therapeutics makes up 1.2% of New England Research & Management Inc.’s portfolio, making the stock its 24th largest position. New England Research & Management Inc.’s holdings in United Therapeutics were worth $2,396,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC lifted its position in United Therapeutics by 85.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,585 shares of the biotechnology company’s stock valued at $594,000 after acquiring an additional 1,191 shares in the last quarter. Cardinal Capital Management lifted its position in United Therapeutics by 20.2% in the 1st quarter. Cardinal Capital Management now owns 9,955 shares of the biotechnology company’s stock valued at $2,287,000 after acquiring an additional 1,675 shares in the last quarter. Janiczek Wealth Management LLC lifted its position in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares in the last quarter. Gateway Investment Advisers LLC bought a new stake in United Therapeutics in the 1st quarter valued at $220,000. Finally, Atwood & Palmer Inc. lifted its position in United Therapeutics by 6.2% in the 1st quarter. Atwood & Palmer Inc. now owns 63,597 shares of the biotechnology company’s stock valued at $14,610,000 after acquiring an additional 3,725 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Finally, HC Wainwright reissued a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $312.22.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $318.55 on Friday. The company’s 50 day moving average price is $274.77 and its two-hundred day moving average price is $244.09. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $321.80. The firm has a market cap of $14.13 billion, a PE ratio of 15.06, a PEG ratio of 1.39 and a beta of 0.49. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.63 by $0.54. The business had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same quarter last year, the business posted $4.86 EPS. Equities research analysts predict that United Therapeutics Co. will post 24.73 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $232.37, for a total transaction of $1,394,220.00. Following the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $8,530,302.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Christopher Causey sold 2,240 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $232.37, for a total transaction of $1,394,220.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $8,530,302.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 126,344 shares of company stock worth $32,426,462. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.